ThyroSeq Announces New Data On Utilization Of ThyroSeq v3 Genomic Classifier At AACE 2018 Meeting
ThyroSeq Announces New Data On Utilization Of ThyroSeq v3 Genomic Classifier At AACE 2018 Meeting
BOSTON, May 15, 2018 /PRNewswire/ -- ThyroSeq® announced today that it will present performance data on utilization of ThyroSeq v3 Genomic Classifier at the upcoming American Association of Clinical Endocrinologists (AACE) 27th Annual Scientific & Clinical Congress. ThyroSeq v3 Genomic Classifier is based on a robust genomic analysis of 112 genes for >12,000 DNA variants, >120 gene fusions, copy number alterations and gene expression alterations. ThyroSeq has more than 10 years of experience with testing indeterminate cytology nodules for molecular markers and over 5 years of utilizing next-generation sequencing. It relies on a proprietary database containing outcomes on thousands of patients with specific genetic alterations to uniquely provide interpretation of the test results, including cancer probability and aggressiveness. This information is essential to assist physicians with offering the most appropriate management for patients with thyroid nodules that have indeterminate cytology. The new "real world" data from more than 20 institutions on 3,783 FNA samples with indeterminate cytology will be presented at the AACE Annual Congress, which is being held May 16-20 in Boston.
"In this large consecutive series of indeterminate cytology nodules tested by ThyroSeq v3 GC, 62% of cases yielded a negative test result, so that diagnostic surgery may be avoided in most of these patients. Among test-positive nodules, ThyroSeq provided more precise assessment of cancer likelihood and potential for recurrence, allowing physicians to offer more individualized patient management," said Yuri Nikiforov, MD, PhD, one of the authors of the study.
The following abstract will provide information on the utility of ThyroSeq for diagnosis and management of patients with indeterminate cytology nodules in multiple clinical centers in the United States:
Title: Real World Experience with
ThyroSeq v3 Genomic Classifier in
Thyroid Nodules with
Indeterminate Cytology: Results
of Testing of the First 3,783
Consecutive Samples (Poster
#1221)
Presenter: Yuri E. Nikiforov, M.D.,
University of Pittsburgh Medical
Center
Date/Time: Saturday, May 19, 10:00 -11:00
a.m. Eastern Time
Location: Hynes Convention Center, Exhibit
Hall
ThyroSeq will also host the following reception and presentation
event supported by Sonic Healthcare USA:
Title: Applying Genomic Science to
Thyroid FNA Diagnosis
Presenters: Yuri E. Nikiforov, M.D., PhD,
University of Pittsburgh Medical
Center
Steven Hodak, MD, NYU School of
Medicine
Date/Time: Thursday, May 17, 7:15-9:15 p.m.
Eastern Time
Location: Top of the Hub, 800 Boylston
Street, Boston, MA
About ThyroSeq
ThyroSeq is an innovative proprietary test, which through 10 years of continuous refinement incorporates all major scientific discoveries and utilizes advanced technology to provide the most accurate diagnosis of whether malignant disease is present in thyroid nodules. For more information, visit www.ThyroSeq.com.
MEDIA CONTACT
Jeanine Wilson
(917)841-8565
thyroseq@wmediagroup.com
View original content with multimedia:http://www.prnewswire.com/news-releases/thyroseq-announces-new-data-on-utilization-of-thyroseq-v3-genomic-classifier-at-aace-2018-meeting-300648710.html
SOURCE ThyroSeq
